 WALTHAM, Mass., Sept. 15, 2021 PRNewswire -- Syndax Pharmaceuticals, Inc. Syndax, the Company or we Nasdaq: SNDX, a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the expansion of its Board of Directors to nine members with the appointment of Martin H. 